ASRT Stock Forecast & Price Target

Assertio Holdings Inc. has demonstrated a significant improvement in its gross margin, which increased to 70% from 65% in the prior year quarter, primarily due to a reduction in inventory write-downs and the completion of ROLVEDON inventory step-up amortization. The company anticipates continued sequential growth in ROLVEDON sales over the remainder of the year, indicating a positive trend in revenue generation. Moreover, as inventory write-downs diminish, gross margins are expected to improve further, providing a strong foundation for financial stability and potential profitability.

Assertio Holdings Inc. has experienced a decline in net product sales for both Indocin and ROLVEDON, with Indocin sales dropping from $8.7 million to $5.5 million in 1Q24, primarily due to increased generic competition impacting volume and pricing. ROLVEDON also saw a decrease in sales from $14.5 million to $13.1 million in 1Q25, attributed to lower pricing despite a slight increase in volume. Furthermore, the company reported a net loss of $0.14 per share in 1Q25, contrasting sharply with prior projections of a $63.9 million loss, highlighting significant challenges in maintaining profitability amidst competitive pressures and pricing strategies.